Alto Neuroscience, a clinical-stage biopharmaceutical company based in Los Altos, California, focuses on developing psychiatric drugs using its Precision Psychiatry Platform. The company has five clinical-stage assets targeting depression and schizophrenia, with an IPO on February 2, 2024.
ANRO filed a patent for "method of treatment and selection of patients benefiting from agomelatine based on eeg measurements" on Tue, May 21, 2024. The patent was officially published on Thu, February 13, 2025.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
